Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim–sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases

References

• Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487–98.
   PubMed Web of Science ®Google Scholar
• Catherinot E, Lanternier F, Bougnoux ME, Lecuit M, Couderc LJ, Lortholary O. Pneumocystis jirovecii pneumonia. Infect Dis Clin North Am. 2010;24:107–38.
   PubMed Web of Science ®Google Scholar
• Godeau B, Coutant-Perronne V, Le Thi Huong D, Guillevin L, Magadur G, De Bandt M, DeIlion S, Rossert J, Rostoker G, Piette JC, et al. Pneumocystis carinii pneumonia in the course of con-nective tissue disease: report of 34 cases. J Rheumatol. 1994;21:246–51.
   PubMed Web of Science ®Google Scholar
• Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42: 780–9.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Manta KG, Betsi GI, Pappas G. Infection-related morbidity and mortality in patients with connective tissue dis-eases: a systematic review. Clin Rheumatol. 2007;26:663–70.
   PubMed Web of Science ®Google Scholar
• Walzer PD, Smulian AG. Pneumocystis species. In: Mandel GL, Bennett JE, Dolin R (eds) Mandel, Douglas and Bennett's prin-ciples and practice of infectious diseases, vol. 2. 6th edn. Phila-delphia: Churchill Livingstone; 2004. p. 3080–94.
   Google Scholar
• Mansharamani NG, Garland R, Delaney D, Koziel H. Manage-ment and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest. 2000;118:704–11.
   PubMed Web of Science ®Google Scholar
• Harigai M, Koike R, Pneumocystis Pneumonia under Anti-Tumor Necrosis Factor Therapy (PAT) Study Group. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;357:1874–6.
   Google Scholar
• Sowden E, Carmichael AJ. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis. 2004;4:42.
   PubMed Web of Science ®Google Scholar
• Suryaprasad A, Stone JH. When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insight from three cases com-plicating autoimmune diseases. Arthritis Rheum. 2008;59:1034–9.
   PubMed Web of Science ®Google Scholar
• Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for pneu-mocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2007;18:CD005590.
   Google Scholar
• Takabayashi K, Kurasawa K, Yamazaki S, Sugiyama T, Mat-sumura R,Yoshida H, Koike T, et al. Pulmonary opportunistic infections in patients with autoimmune diseases (in Japanese). Nihon Naika Gakkai Zasshi. 1989;78:1293–8.
   PubMedGoogle Scholar
• Reilly TP, Ju C. Mechanistic perspectives on sulfonamide-induced cutaneous drug reactions. Curr Opin Allergy Clin Immunol. 2002;2:307–1.
   PubMed Web of Science ®Google Scholar
• Jaffe HS, Abrams DI, Ammann AJ, Lewis BJ, Golden JA. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet. 1983;22:1109–11.
   Google Scholar
• Ryan TM. Significance tests for multiple comparison of propor-tions, variances, and other statistics. Psychol Bull. 1960;5: 318–28.
   Web of Science ®Google Scholar
• Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis. 1982;4:426–8.
   PubMedGoogle Scholar
• Shionogi (Osaka, Japan). Baktar. Drug interview form (in Japa-nese). 2009. Available at: http://www.info.pmda.go.jp/go/inter view/1/340018_6290100D1088_1_008_1F.
   Google Scholar
• Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J, et al. Pneumocystis carinii pneumonia: a compari-son between patients with the acquired immunodeficiency syn-drome and patients with other immunodeficiencies. Ann Intern Med. 1984;100:663–71.
   PubMed Web of Science ®Google Scholar
• Davis CM, Shearer WT. Diagnosis and management of HIV drug hypersensitivity. J Allergy Clin Immunol. 2008;121:826–32.
   PubMed Web of Science ®Google Scholar
• Lin D, Li WK, Rieder MJ. Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole. Cochrane Database Syst Rev. 2007;2:CD005646.
   Google Scholar
• Antonen JA, Markula KP, Pertovaara MI, Pastemack AT. Adverse drug reactions in Sjögren's syndrome. Frequent allergic reactions and a specific trimethoprim-associated systemic reaction. Scand J Rheumatol. 1999;28:157–9.
   Google Scholar
• Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Tri-methoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996;335:16–20.
   PubMed Web of Science ®Google Scholar
• Pope J, Jerome D, FenIon D, Krizova A, Ouimet J. Frequency of adverse drug reactions in patients with systemic lupus erythe-matosus. J Rheumatol. 2003;30:480–4.
   Google Scholar
• Schneider MM, Hoepelman AT, Eeftinck Schattenkerk JK, Niel-sen TL, van der Graaf Y, Frissen JP, van der Ende IM, Kolsters AF, Borleffs JC. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immu-nodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med. 1992;327:1836–41.
   Google Scholar
• Hardy WD, Feinberg J, Finkelstein DM, Power ME, He W, Kaczka C, Frame PT, Holmes M, Waskin H, Fass RJ, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syn-drome. AIDS Clinical Trials Group Protocol 021. N Engl J Med. 1992;327:1842–8.
   PubMed Web of Science ®Google Scholar
• Okada J, Kadoya A, Rana M, Ishikawa A, Iikuni Y, Kondo H. Efficacy of sulfamethoxazole-trimethoprim administration in the prevention of Pneumocystis carinii pneumonia in patients with connective tissue disease. Kansenshogaku Zasshi. 1999;73:1123–9.
   PubMedGoogle Scholar
• Soejima M, Sugiura T, Kawaguchi Y, Kawamoto M, Katsumata Y, Takagi K, Nakajima A, Mitamura T, Mimori A, Hara M, Kamatani N. Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus. Arthritis Res Ther. 2007;9:R23.
   Google Scholar
• Reilly TP, Ju C. Mechanistic perspectives on sulfonamide-induced cutaneous drug reactions. Curr Opin Allergy Clin Immunol. 2002;2:307–15.
   PubMed Web of Science ®Google Scholar
• Naisbitt DJ, Farrell J, Gordon SF, Maggs JL, Burkhart C, Pichler WJ, Pirmohamed M, Park BK. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major his-tocompatibility complex-restricted antigen presentation. Mol Pharmacol. 2002;62:628–37.
   PubMed Web of Science ®Google Scholar
• Eloranta ML, Lövgren T, Finke D, Mathsson L, Ronnelid J, Kastner B, Alm GV, Riinnblom L. Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum. 2009;60: 2418–27.
   PubMed Web of Science ®Google Scholar
• Okada J, Hamana T, Kondo H. Anti-U1RNP antibody and aseptic meningitis in connective tissue diseases. Scand J Rheumatol. 2003;32: 247–52.
   Google Scholar
• Fujita Y, Fujii T, Nakashima R, Tanaka M, Mimori T. Aseptic meningitis in mixed connective tissue disease: cytokine and anti-U1RNP antibodies in cerebrospinal fluids from two different cases. Mod Rheumatol. 2008;18: 184–8.
   Google Scholar
• Joffe AM, Farley JD, Linden D, Goldsand G. Trimethoprim-sulfamethoxazole-associated aseptic meningitis: case reports and review of the literature. Am J Med. 1989;87:332–8.
   PubMed Web of Science ®Google Scholar
• Gilroy N, Gottlieb T, Spring P, Peiris O. Trimethoprim-induced aseptic meningitis and uveitis. Lancet. 1997;350:112.
   PubMed Web of Science ®Google Scholar
• Kimura M, Tanaka S, Ishikawa A, Endo H, Hirohata S, Kondo H. Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease. Rheumatol Int. 2008;28:673–6.
   PubMed Web of Science ®Google Scholar